CA2856918C - Use of chemically modified heparin derivates in sickle cell disease - Google Patents
Use of chemically modified heparin derivates in sickle cell disease Download PDFInfo
- Publication number
- CA2856918C CA2856918C CA2856918A CA2856918A CA2856918C CA 2856918 C CA2856918 C CA 2856918C CA 2856918 A CA2856918 A CA 2856918A CA 2856918 A CA2856918 A CA 2856918A CA 2856918 C CA2856918 C CA 2856918C
- Authority
- CA
- Canada
- Prior art keywords
- heparin
- kda
- chemically modified
- polysaccharide chains
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 137
- 208000007056 sickle cell anemia Diseases 0.000 title claims abstract description 39
- 230000000694 effects Effects 0.000 claims abstract description 33
- 229920000669 heparin Polymers 0.000 claims description 120
- 229960002897 heparin Drugs 0.000 claims description 91
- 150000004676 glycans Polymers 0.000 claims description 41
- 150000004804 polysaccharides Polymers 0.000 claims description 32
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 18
- 239000004019 antithrombin Substances 0.000 claims description 14
- 150000002016 disaccharides Chemical class 0.000 claims description 13
- 230000009467 reduction Effects 0.000 claims description 13
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical class OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 claims description 9
- 230000002429 anti-coagulating effect Effects 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical group OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 claims description 5
- 150000001720 carbohydrates Chemical group 0.000 claims description 5
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 41
- 239000000243 solution Substances 0.000 description 61
- 238000000034 method Methods 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 230000008569 process Effects 0.000 description 37
- 210000003743 erythrocyte Anatomy 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 21
- 108010035766 P-Selectin Proteins 0.000 description 20
- 102000008212 P-Selectin Human genes 0.000 description 20
- 239000000047 product Substances 0.000 description 18
- 229960005062 tinzaparin Drugs 0.000 description 18
- 238000003756 stirring Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 230000014508 negative regulation of coagulation Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 208000034158 bleeding Diseases 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 12
- 210000002889 endothelial cell Anatomy 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 239000013049 sediment Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 102000003816 Interleukin-13 Human genes 0.000 description 7
- 108090000176 Interleukin-13 Proteins 0.000 description 7
- 108091006629 SLC13A2 Proteins 0.000 description 7
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229940126534 drug product Drugs 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000000366 juvenile effect Effects 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229940087051 fragmin Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000002628 heparin derivative Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 102000019997 adhesion receptor Human genes 0.000 description 2
- 108010013985 adhesion receptor Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010079356 FIIa Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- OHJKXVLJWUPWQG-PNRHKHKDSA-N Heparinsodiumsalt Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](O)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 OHJKXVLJWUPWQG-PNRHKHKDSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- PRDZVHCOEWJPOB-IVMDWMLBSA-N N-sulfo-D-glucosamine Chemical compound OC[C@H]1OC(O)[C@H](NS(O)(=O)=O)[C@@H](O)[C@@H]1O PRDZVHCOEWJPOB-IVMDWMLBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101710187074 Serine proteinase inhibitor Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010051895 acute chest syndrome Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001858 anti-Xa Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002339 anti-haemostatic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical group N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940095443 innohep Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 229950008422 sevuparin sodium Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 201000009225 splenic sequestration Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2011/051538 WO2013095215A1 (en) | 2011-12-19 | 2011-12-19 | Low anticoagulant heparins |
| SEPCT/SE2011/051538 | 2011-12-19 | ||
| PCT/SE2012/051429 WO2013095277A1 (en) | 2011-12-19 | 2012-12-19 | Use of chemically modified heparin derivates in sickle cell disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2856918A1 CA2856918A1 (en) | 2013-06-27 |
| CA2856918C true CA2856918C (en) | 2017-07-04 |
Family
ID=48668926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2856918A Expired - Fee Related CA2856918C (en) | 2011-12-19 | 2012-12-19 | Use of chemically modified heparin derivates in sickle cell disease |
| CA2856477A Active CA2856477C (en) | 2011-12-19 | 2012-12-19 | Low anticoagulant heparins |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2856477A Active CA2856477C (en) | 2011-12-19 | 2012-12-19 | Low anticoagulant heparins |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9480702B2 (OSRAM) |
| EP (2) | EP2794667B1 (OSRAM) |
| JP (2) | JP6703806B2 (OSRAM) |
| CN (1) | CN104053675B (OSRAM) |
| AU (1) | AU2012354226B2 (OSRAM) |
| BR (1) | BR112014014673B1 (OSRAM) |
| CA (2) | CA2856918C (OSRAM) |
| CY (2) | CY1120197T1 (OSRAM) |
| DK (2) | DK2794667T3 (OSRAM) |
| ES (2) | ES2669055T3 (OSRAM) |
| HR (2) | HRP20180726T1 (OSRAM) |
| HU (2) | HUE037554T2 (OSRAM) |
| IL (1) | IL232903A (OSRAM) |
| IN (1) | IN2014MN01056A (OSRAM) |
| MX (1) | MX358439B (OSRAM) |
| MY (1) | MY170069A (OSRAM) |
| NO (2) | NO2794667T3 (OSRAM) |
| PH (1) | PH12014501387B1 (OSRAM) |
| PL (2) | PL2794667T3 (OSRAM) |
| PT (2) | PT2794666T (OSRAM) |
| RS (2) | RS57214B1 (OSRAM) |
| SI (2) | SI2794667T1 (OSRAM) |
| SM (2) | SMT201800217T1 (OSRAM) |
| TN (2) | TN2014000236A1 (OSRAM) |
| WO (3) | WO2013095215A1 (OSRAM) |
| ZA (1) | ZA201403654B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013095215A1 (en) | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| CA2856492C (en) | 2011-12-19 | 2017-01-10 | Dilafor Ab | Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use |
| GB2515315A (en) | 2013-06-19 | 2014-12-24 | Dilafor Ab | New Processes |
| ES2749076T3 (es) * | 2014-04-30 | 2020-03-19 | Inst Nat Sante Rech Med | DNasa para uso en el tratamiento de crisis vaso-oclusivas |
| EP2965764A1 (en) * | 2014-07-11 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating vaso-occlusive crisis |
| CN105504097B (zh) * | 2015-12-30 | 2018-07-03 | 深圳市海普瑞药业集团股份有限公司 | 一种硫酸化肝素寡糖及其制备方法和应用 |
| CN108424474B (zh) * | 2017-02-15 | 2023-07-25 | 清华大学 | 去抗凝肝素衍生物及其用于炎症性肠病的治疗 |
| CA3097047A1 (en) * | 2018-04-13 | 2019-10-17 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels |
| CN109481692A (zh) * | 2018-11-30 | 2019-03-19 | 东南大学 | 一种青蒿琥酯肝素衍生物及其药物组合物和应用 |
| WO2023192339A1 (en) * | 2022-03-29 | 2023-10-05 | The Penn State Research Foundation | Granular hydrogel bioinks with preserved interconnected porosity and methods for making and using the same |
| WO2023215594A1 (en) | 2022-05-05 | 2023-11-09 | Venture Health Studio, Llc | Magnetic power distribution assembly |
| WO2023239711A1 (en) * | 2022-06-06 | 2023-12-14 | Ihp Therapeutics Inc. | Chemically modified heparin |
| CN115448994B (zh) * | 2022-09-28 | 2023-08-01 | 山东大学 | 一种可中和抗凝低分子量肝素及其制备方法和应用 |
| EP4580751A2 (en) | 2022-09-29 | 2025-07-09 | Adora Animal Health Corporation | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions |
| GB2625581A (en) | 2022-12-21 | 2024-06-26 | Modus Therapeutics Ab | New medical use |
| WO2024170746A1 (en) | 2023-02-17 | 2024-08-22 | Modus Therapeutics Ab | New medical use of sevuparin in the treatment of endotoxemia |
| GB2627263A (en) * | 2023-02-17 | 2024-08-21 | Modus Therapeutics Ab | New medical use |
| CN116854838A (zh) * | 2023-06-30 | 2023-10-10 | 重庆望业药物研究有限公司 | 低分子多糖及其制备方法与应用 |
| GB202407366D0 (en) * | 2024-05-23 | 2024-07-10 | Glycos Biomedical Ltd | Preparation of medium molecular weight heparin |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1136620A (en) | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
| FR2614026B1 (fr) | 1987-04-16 | 1992-04-17 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
| ES2054975T3 (es) * | 1988-10-07 | 1994-08-16 | Hoechst Ag | Composiciones antimalaricas que emplean quinidina, artemisinina y sus derivados. |
| SE9002550D0 (sv) | 1990-08-01 | 1990-08-01 | Kabivitrum Ab | Heparinfragment |
| SE9003181D0 (sv) | 1990-10-04 | 1990-10-04 | Kabivitrum Ab | Use of heparin fraction |
| US5250519A (en) * | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| US5280016A (en) * | 1991-03-29 | 1994-01-18 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| JPH0532703A (ja) * | 1991-07-26 | 1993-02-09 | Terumo Corp | 低分子量ヘパリン誘導体の製造法 |
| AU5442594A (en) | 1992-10-13 | 1994-05-09 | Virginia Commonwealth University | Use of non-anticoagulant heparin for treating ischemia/reperfusion injury |
| US5527785A (en) * | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
| DE69623840D1 (de) * | 1995-03-31 | 2002-10-31 | Hamilton Civic Hospitals Res | Zusammensetzung zur Hemmung der Thromboseentstehung |
| US5993810A (en) | 1996-03-15 | 1999-11-30 | Lebovitz; Shamir Israel | Method of softening or ripening the cervix of a female mammal using collagenase |
| US5767269A (en) | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
| WO1998016559A1 (fr) | 1996-10-15 | 1998-04-23 | Toray Industries, Inc. | Agent de maturation des canaux cervicaux |
| GB9711443D0 (en) | 1997-06-03 | 1997-07-30 | Leo Pharm Prod Ltd | Chemical suppositions |
| CA2310422A1 (en) * | 1997-11-20 | 1999-06-03 | Ikuo Yamashina | Low-molecular heparin modification and remedy for skin ulcer |
| US6596705B1 (en) * | 1998-02-09 | 2003-07-22 | The Regents Of The University Of California | Inhibition of L-selectin and P-selection mediated binding using heparin |
| EP1059304B1 (en) | 1998-02-26 | 2006-04-26 | Seikagaku Corporation | Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient |
| US6028061A (en) * | 1998-06-18 | 2000-02-22 | Children's Medical Center Corp | Angiogenesis inhibitors and use thereof |
| CA2305619C (en) * | 1998-07-31 | 2008-05-20 | Seikagaku Corporation | Novel glycosaminoglycan and pharmaceutical composition using the same as active ingredient |
| AU782661B2 (en) * | 1999-06-30 | 2005-08-18 | Hamilton Civic Hospitals Research Development, Inc. | Heparin compositions that inhibit clot associated coagulation factors |
| JP4897991B2 (ja) * | 1999-07-23 | 2012-03-14 | ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ | 超低分子量ヘパリン組成物 |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| JP4585072B2 (ja) * | 2000-02-29 | 2010-11-24 | 扶桑薬品工業株式会社 | ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物 |
| CA2422059C (en) * | 2000-09-12 | 2012-05-15 | Massachusetts Institute Of Technology | Methods and products related to low molecular weight heparin |
| SE521676C2 (sv) | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
| US20040072796A1 (en) | 2002-04-18 | 2004-04-15 | Embury Stephen H. | Method and composition for preventing pain in sickle cell patients |
| US8071569B2 (en) * | 2002-09-20 | 2011-12-06 | Mousa Shaker A | Oxidized heparin fractions and their use in inhibiting angiogenesis |
| EP1582531A1 (en) | 2004-03-24 | 2005-10-05 | Aventis Pharma S.A. | Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products |
| EP1758557B1 (en) * | 2004-05-11 | 2011-07-13 | Egalet Ltd. | Swellable dosage form comprising gellan gum |
| US20060040896A1 (en) | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| US7741311B2 (en) * | 2005-01-03 | 2010-06-22 | Shaker Mousa | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing |
| EP1906975A4 (en) | 2005-07-22 | 2010-10-06 | Trf Pharma Inc | METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE |
| JP2009507209A (ja) * | 2005-07-22 | 2009-02-19 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | ヘパリン組成物およびセレクチン阻害 |
| AU2007267561B2 (en) * | 2006-05-25 | 2012-05-17 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
| WO2009007224A1 (en) * | 2007-07-10 | 2009-01-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Low molecular weight heparin derivatives having neuroprotective activity |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8592393B2 (en) * | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| ES2567079T3 (es) * | 2007-11-02 | 2016-04-19 | Momenta Pharmaceuticals, Inc. | Composiciones de polisacáridos que no son anticoagulantes |
| WO2009073184A1 (en) | 2007-12-03 | 2009-06-11 | Florida State University Research Foundation, Inc. | Compositions for inducing labor and associated methods |
| KR101594552B1 (ko) * | 2008-04-04 | 2016-02-17 | 유니버시티 오브 유타 리서치 파운데이션 | 알킬화된 반합성 글리코사미노글리코산 에테르 및 이의 제조 및 사용 방법 |
| CN102105427A (zh) * | 2008-07-25 | 2011-06-22 | 阿尔法制药有限公司 | 粒度直径范围(D90)为大于3μm至约10μm的阿托伐醌 |
| DK2419736T3 (da) | 2009-04-16 | 2014-04-22 | Momenta Pharmaceuticals Inc | Fremgangsmåder til vurdering af aktivitet af en polysaccharidsammensætning |
| AU2010268756A1 (en) * | 2009-06-30 | 2012-01-19 | The Walter And Eliza Hall Institute Of Medical Research | Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity |
| CA2856492C (en) | 2011-12-19 | 2017-01-10 | Dilafor Ab | Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use |
| WO2013095215A1 (en) | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| US20150057226A1 (en) | 2012-03-26 | 2015-02-26 | Dilafor Ab | Method for treatment of labor arrest |
| EP2830635A4 (en) | 2012-03-26 | 2016-03-16 | Dilafor Ab | COMBINATION TREATMENT OF ILLUSTRATED SULFATED GLYCOSAMINOGLYCANES |
-
2011
- 2011-12-19 WO PCT/SE2011/051538 patent/WO2013095215A1/en not_active Ceased
-
2012
- 2012-12-19 MX MX2014006956A patent/MX358439B/es active IP Right Grant
- 2012-12-19 AU AU2012354226A patent/AU2012354226B2/en active Active
- 2012-12-19 WO PCT/SE2012/051429 patent/WO2013095277A1/en not_active Ceased
- 2012-12-19 HR HRP20180726TT patent/HRP20180726T1/hr unknown
- 2012-12-19 NO NO12860938A patent/NO2794667T3/no unknown
- 2012-12-19 CA CA2856918A patent/CA2856918C/en not_active Expired - Fee Related
- 2012-12-19 CN CN201280062042.7A patent/CN104053675B/zh active Active
- 2012-12-19 US US14/366,603 patent/US9480702B2/en active Active
- 2012-12-19 MY MYPI2014001796A patent/MY170069A/en unknown
- 2012-12-19 SM SM20180217T patent/SMT201800217T1/it unknown
- 2012-12-19 IN IN1056MUN2014 patent/IN2014MN01056A/en unknown
- 2012-12-19 BR BR112014014673-0A patent/BR112014014673B1/pt active IP Right Grant
- 2012-12-19 PT PT128593845T patent/PT2794666T/pt unknown
- 2012-12-19 PT PT128609385T patent/PT2794667T/pt unknown
- 2012-12-19 ES ES12860938.5T patent/ES2669055T3/es active Active
- 2012-12-19 EP EP12860938.5A patent/EP2794667B1/en active Active
- 2012-12-19 HU HUE12859384A patent/HUE037554T2/hu unknown
- 2012-12-19 HR HRP20180725TT patent/HRP20180725T1/hr unknown
- 2012-12-19 DK DK12860938.5T patent/DK2794667T3/en active
- 2012-12-19 PL PL12860938T patent/PL2794667T3/pl unknown
- 2012-12-19 RS RS20180574A patent/RS57214B1/sr unknown
- 2012-12-19 JP JP2014547145A patent/JP6703806B2/ja active Active
- 2012-12-19 HU HUE12860938A patent/HUE037555T2/hu unknown
- 2012-12-19 RS RS20180552A patent/RS57213B1/sr unknown
- 2012-12-19 SI SI201231283T patent/SI2794667T1/en unknown
- 2012-12-19 ES ES12859384.5T patent/ES2668273T3/es active Active
- 2012-12-19 PL PL12859384T patent/PL2794666T3/pl unknown
- 2012-12-19 US US14/366,570 patent/US9480701B2/en active Active
- 2012-12-19 WO PCT/SE2012/051428 patent/WO2013095276A1/en not_active Ceased
- 2012-12-19 CA CA2856477A patent/CA2856477C/en active Active
- 2012-12-19 SM SM20180218T patent/SMT201800218T1/it unknown
- 2012-12-19 SI SI201231282T patent/SI2794666T1/en unknown
- 2012-12-19 DK DK12859384.5T patent/DK2794666T3/en active
- 2012-12-19 NO NO12859384A patent/NO2794666T3/no unknown
- 2012-12-19 EP EP12859384.5A patent/EP2794666B1/en active Active
-
2014
- 2014-05-20 ZA ZA2014/03654A patent/ZA201403654B/en unknown
- 2014-05-29 TN TNP2014000236A patent/TN2014000236A1/en unknown
- 2014-05-29 TN TNP2014000237A patent/TN2014000237A1/en unknown
- 2014-06-01 IL IL232903A patent/IL232903A/en active IP Right Grant
- 2014-06-18 PH PH12014501387A patent/PH12014501387B1/en unknown
-
2018
- 2018-05-10 CY CY20181100483T patent/CY1120197T1/el unknown
- 2018-05-10 CY CY20181100482T patent/CY1120194T1/el unknown
- 2018-06-12 JP JP2018112162A patent/JP2018154848A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2856918C (en) | Use of chemically modified heparin derivates in sickle cell disease | |
| CA2856492C (en) | Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use | |
| JP6980018B2 (ja) | 内因系テンナーゼ複合体を阻害するオリゴ糖、その製造方法と用途 | |
| HK1199893B (en) | Use of chemically modified heparin derivates in sickle cell disease | |
| HK1200471B (en) | Low anticoagulant heparins | |
| NZ625096B2 (en) | Low anticoagulant heparins | |
| HK1202883B (en) | Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160916 |
|
| MKLA | Lapsed |
Effective date: 20210831 |
|
| MKLA | Lapsed |
Effective date: 20191219 |